DiabetologyNews.net

Diabetology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Cardiobase

Patients with newly diagnosed type 2 diabetes: prevalence of cardiovascular autonomic neuropathy


Cardiovascular autonomic diabetic neuropathy ( CAN ) is a serious complication of diabetes. No reliable data on the prevalence of cardiovascular autonomic neuropathy among patients with newly diagnosed type 2 diabetes are available.
Therefore, the aim of the study, Verona Newly Diagnosed Type 2 Diabetes Study ( VNDS ), was to estimate the prevalence of cardiovascular autonomic neuropathy among patients with newly diagnosed type 2 diabetic.

A cohort of 557 patients with newly diagnosed type 2 diabetes with cardiovascular autonomic test results available was selected.
Early and confirmed neuropathy were assessed using a standardized methodology and their prevalences determined. A multivariate logistic regression analysis was modeled to study the factors associated with cardiovascular autonomic neuropathy.

In the entire cohort, the prevalence of confirmed cardiovascular autonomic neuropathy was 1.8%, whereas that of early cardiovascular autonomic neuropathy was 15.3%.

Prevalence did not differ between men and women.

In the multivariate analyses BMI ( body mass index ) results were independently and significantly associated with cardiovascular autonomic neuropathy after adjusting for age, sex, hemoglobin A1c, pulse pressure, triglyceride-to-HDL cholesterol ratio, kidney function parameters, and antihypertensive treatment.

In conclusion, cardiovascular autonomic neuropathy could be detected very early in type 2 diabetes.
This study may suggest the importance of performing standardized cardiovascular autonomic tests after diagnosis of type 2 diabetes. ( Xagena )

Zoppini G et al, Diabetes Care 2015; Epub ahead of print

XagenaMedicine_2015



Indietro